2. Cowie C.C., Rust K.F., Byrd-Holt D.D., Eberhardt M.S., Flegal K.M., Engelgau M.M., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263.

3. Brown J.S., Vittinghoff E., Lin F., Nyberg L.M., Kusek J.W., Kanaya A.M. Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001 –2002. Diabetes Care 2006;29:1307.

4. Shabudina N.O. Clinical manifestations and treatment of urinary disturbances in patients with type II diabetes. Avtoref. dis. kand. med. nauk, 2014. Russian (Шабудина Н.О. Клиническое течение и лечение нарушений мочеиспускания у больных сахарным диабетом 2 типа. Автореф. дисс. канд. мед. наук, 2014).

5. Ostrouhova E.N. A diagnosis and treatment of type 2 diabetes is a multidisciplinary problem. Problemy endokrinologii. 2013;59(1):44–48. Russian (Остроухова E.H. Выявление и лечение сахарного диабета 2 типа – проблема междисциплинарная. Проблемы эндокринологии. 2013;59(1):44–48).

6. Suncov Ju.I., Bolotskaja L.L., Maslova O.V., Kazakov I.V. The epidemiology of diabetes and a prognosis of its prevalence in Russian Federation. Saharnyj diabet. 2011;1:15–18. Russian (Сунцов Ю.И., Болотская Л.Л., Маслова О.В., Казаков И.В. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации. Сахарный диабет. 2011;1:15–18.)

7. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311–321.

8. Frimodt-Møller C. Diabetic cystopathy. A review of the urodynamic and clinical features of neurogenic bladder dysfunction in diabetes mellitus. Dan Med Bull 1978;25:49–60.

9. Lee W.C., Wu H.P., Tai T.Y., Liu S.P., Chen J., Yu H.J. Effects of diabetes on female voiding behavior. J Urol 2004;172:989–992.

10. Kebapci N., Yenilmez A., Efe B., Entok E., Demirustu C. Bladder dysfunction in type 2 diabetic patients. Neurourol Urodyn 2007;26:814–819.

11. Frimodt-Møller C. Diabetic cystopathy: epidemiology and related disorders. Ann Intern Med. 1980;92(2 Pt 2):318–321.

12. Kaplan S.A., Te A.E., Blaivas J.G. Urodynamic ndings in patients with diabetic cystopathy. J Urol 1995;153:342–344.

13. Brown J. S. Diabetic cystopathy — what does it mean? J. Urol. 2009;181(1):13–14.

14. Yoshimura N.,  Chancellor M.B.,  Andersson K.E. Recent ad­ vances in understanding the biology of diabetes­associated blad­ der complications and novel therapy. BJU Int. 2005;95:733–738.

15. Al-Shukri S.H., Kuz'min I.V., Shabudina N.O. Lower urinary tract dysfunction in patients with diabetes. Ural'skij medicinskij zhurnal. 2012;3:114–119. Russian (Аль-ШукриС.Х., Кузьмин И.В., Шабудина Н.О. Дисфункции нижних мочевых путей у больных сахарным диабетом. Уральский медицинский журнал. 2012;3:114–119).

16. Hill S R, Fayyad A M, Jones G R. Diabetes mellitus and female lower urinary tract symptoms: a review. Neurourol. Urodyn. 2008;27(5):362–367.

17. Ueda T.,  Yoshimura N.,  Yoshida O. Diabetic cystopathy: re­ lationship to autonomic neuropathy detected by sympathetic skin response. J. Urol. (Baltimore). 1997;157(2):580–584.

18. Hunter K.F.,  Moore K.N. Diabetes­associated bladder dys­ function in the older adult. Geriatr. Nurs. 2003;24:138–145.

19. Al-Shukri S.H., Kuz'min I.V., Shabudina N.O. Urodynamic changes in lower urinary tract in patients with diabetic cystopathy. Urologicheskie vedomosti. 2012;4. Ruddian (Аль-Шукри С.Х., Кузьмин И.В., Шабудина Н.О. Состояние уродинамики нижних мочевых путей у больных с диабетической цистопатией. Урологические ведомости. 2012;4).

20. McGrother C.W., Donaldson M.M.K. et al. Etiology of overactive bladder: A diet and lifestyle model for diabetes and obesity in older women. Neurourol. Urodyn. 2012; 31(4): 487–495.

21. Ripoli A., Palleschi G., Pastore A.L. et al. Overactive bladder in diabetes mellitus patients: a questionnaire based observational investigation. Neurourol Urodyn. 2013;32(6):592–593.

22. Wen J.G., Huang C.X., Li Z.Z. et al. The effect of diabetes duration on voiding function in people more than 45 year old. Neurourol Urodyn. 2013;32(6):848.

23. Kuz'min I.V., Shabudina N.O. The epidemiology and risk factors of urinary disturbances in patients with diabetes. Urologija. 2014;6:114–118. Russian (Кузьмин И.В., Шабудина Н.О. Эпидемиология и факторы риска развития нарушений мочеиспускания у больных сахарным диабетом. Урология. 2014;6:114–118).

24. Yuan Z., Tang Z., He C., Tang W. Diabetic cystopathy: A review. J Diabetes 2015;7:442–447.

25. Saito M., Nakamura I., Miyagawa I. Autoradiographic localization of muscarinic receptors in diabetic rat bladder. Nihon Hinyokika Gakkai Zasshi 1997;88:858–867.

26. Tong Y.C., Chin W.T., Cheng J.T. Alterations in urinary bladder M2-muscarinic receptor protein and mRNA in 2-week streptozotocin-induced diabetic rats. Neurosci Lett 1999;277:173–176.

27. Daneshgari F., Liu G., Imrey P.B. Time dependent changes in diabetic cystopathy in rats include compensated and decompensated bladder function. J Urol 2006;176:380–386.

28. Wu L., Zhang X., Xiao N., Huang Y., Kavran M., Elrashidy R.A., et al. Functional and morphological alterations of the urinary bladder in type 2 diabetic FVB(db/db) mice. J Diabetes Complications 2016;30:778–785.

29. Beshay E., Carrier S. Oxidative stress plays a role in diabetes-induced bladder dysfunction in a rat model. Urology 2004;64:1062–1067.

30. Changolkar A.K., Hypolite J.A., Disanto M., Oates P.J., Wein A.J., Chacko S. Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase. J Urol 2005;173:309–313.

31. Nakamura N., Obayashi H., Fujii M., Fukui M., Yoshimori K., Ogata M., et al. Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic Biol Med 2000;29:17–25.

32. Daneshgari F., Liu G., Birder L., Hanna-Mitchell A.T., Chacko S. Diabetic bladder dysfunction: Current translational knowledge. J Urol 2009;182:S18–26.

33. Steinberg S.F. Oxidative stress and sarcomeric proteins. Circ Res 2013;112:393–405.

34. Yohannes E., Chang J., Christ G.J., Davies K.P., Chance M.R. Proteomics analysis identi es molecular targets related to diabetes mellitus-associated bladder dysfunction. Mol Cell Proteomics 2008;7:1270–1285.

35. Gandhi J., Dagur G., Warren K., Smith N.L., Khan S.A. Genitourinary complications of diabetes mellitus: An overview of pathogenesis, evaluation, and management. Curr Diabetes Rev. 2017;13:498–518.

36. Tong Y.C., Cheng J.T., Hsu C.T. Alterations of M(2)-muscarinic receptor protein and mRNA expression in the urothelium and muscle layer of the streptozotocin-induced diabetic rat urinary bladder. Neurosci Lett 2006;406:216–221.

37. Golbidi S., Laher I. Bladder dysfunction in diabetes mellitus. Front Pharmacol 2010;1:136.

38. Pinna C., Zanardo R., Puglisi L. Prostaglandin-release impairment in the bladder epithelium of streptozotocin-induced diabetic rats. Eur J Pharmacol 2000;388:267–273.

39. Pitre D.A., Ma T., Wallace L.J., Bauer J.A. Time-dependent urinary bladder remodeling in the streptozotocin-induced diabetic rat model. Acta Diabetol 2002;39:23–27.

40. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med. 2002;113(Suppl. 1A):80S–4S.

41. Jackson S. The patient with an overactive bladder – symptoms and quality of life issues. Urology. 1997;57(6A):18–22.

42. Abrams P., Kelleher C.J., Kerr L.A., Rogers R.G. Overactive blad- der significantly affects quality of life. Am. J. Manag. Care. 2000;6:580–590.

43. Al-Shukri S.H., Kuz'min I.V. Quality of life of patients with overactive bladder. Urologicheskie vedomosti. 2011;1(1):21–26. Russian (Аль-Шукри С.Х., Кузьмин И.В. Качество жизни больных с гиперактивностью мочевого пузыря. Урологические ведомости. 2011;1(1):21–26).

44. Kuz'min I.V., Shabudina N.O. Evaluation of quality of life in patients with diabetic and idiopathic overactive bladder. Urologicheskie vedomosti. 2014;IV(1):11–14. Russian (Кузьмин И.В., Шабудина Н.О. Оценка качества жизни больных с диабетической и идиопатической гиперактивностью мочевого пузыря. Урологические ведомости. 2014;IV(1):11–14).

45. EAU Guidelines, 2019. Доступно на www.uroweb.org

46. Khullar V. et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63(2):283–95.